Tevogen Bio Specialty Care Announces Its Top-Line Revenue Forecast For Its Specialty Care Pipeline, Projecting Nearly $1B In Revenue In Its Launch Year And A Cumulative 5-Year Estimate Of Between $18B-$22B

Benzinga · 10/21 20:01
  • Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.
  • Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years.

WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

Pipeline

  • TVGN 489:
    • Treatment of SARS-CoV-2 infection in patients with B cell hematologic cancer

      [part of Tevogen Bio Oncology forecast]
    • Treatment of SARS-CoV-2 infection in patients with other cancers

      [part of Tevogen Bio Oncology forecast]
    • SARS-CoV-2 infection in patients under treatment for rheumatoid arthritis
    • SARS-CoV-2 infection in patients under treatment for and psoriatic arthritis
    • Treatment of Long COVID [part of Tevogen Bio Specialty Care forecast]
  • TVGN 920: Cervical cancer prevention
  • TVGN 930: EBV-associated lymphomas
  • TVGN 960: Mouth and throat cancer
  • TVGN 601: Multiple sclerosis